Skip to main content
Clinical Trials/NCT05350358
NCT05350358
Completed
N/A

A Retrospective Patient Registry on the Long-Term Performance of the Dialine II® Vascular Graft Prosthesis Used in Open Vascular Surgery

Geprovas1 site in 1 country262 target enrollmentMarch 1, 2021

Overview

Phase
N/A
Intervention
Not specified
Conditions
Vascular Aneurysm
Sponsor
Geprovas
Enrollment
262
Locations
1
Primary Endpoint
Primary patency of the prothesis
Status
Completed
Last Updated
4 years ago

Overview

Brief Summary

This clinical study will capture clinical data specific to the performance and safety of the LeMaitre® CARDIAL Dialine II. It is a retrospective, monocenter, post-market safety and performance study. Following the new MDR regulation, this study will allow the clinical data of the prosthesis to be completed in order to renew its CE marking.

Detailed Description

The LeMaitre Cardial Dialine® II Vascular Prostheses (Dialine II) is a knitted PET (Polyethylene Terephthalate) graft manufactured with multifilament yarns and impregnated with bovine origin collagen to achieve a strong and dilatation resistant graft, which eliminates the preclotting step. The bovine collagen is then gradually resorbed by the patient. The Dialine II comes with black guide lines and crimped construction to facilitate implantation. Other design features include: * Thin wall design (0.50+/-0.12mm) with excellent conformability * Special impregnation process for maximum leakage resistance * Water permeability \< 10 ml/cm2/min The Dialine II is indicated for replacement or bypass procedures in aneurysmal and/or occlusive diseases of the abdominal aorta or peripheral arteries. The Dialine II is also indicated for arterial reconstruction in patients requiring systemic heparinization. The unique collagen impregnation results in exceptional resistance to leakage, even under systemic heparinization.

Registry
clinicaltrials.gov
Start Date
March 1, 2021
End Date
December 31, 2021
Last Updated
4 years ago
Study Type
Observational
Sex
All

Investigators

Sponsor
Geprovas
Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • Male and female subjects, ≥ 18 years of age
  • Subject who has undergone surgical treatment for the replacement or bypass in aneurysmal and/or occlusive diseases and for arterial reconstruction in patients requiring systemic heparinization with LeMaitre Cardial Dialine II (between 01JAN2010 and 31JUL2016).

Exclusion Criteria

  • Co-morbidity that in the discretion of the investigator might confound the results.
  • Patient operated on with a Dialine II Vascular prosthesis in conditions where it is connected with another one and that will make impossible to attribute the complication in the case it occurs
  • Infection that may affect the safety or the efficacity of the prothesis

Outcomes

Primary Outcomes

Primary patency of the prothesis

Time Frame: 1 year

Occurence of serious adverse events

Time Frame: 30 days after surgery

Study Sites (1)

Loading locations...

Similar Trials